Telix Pharmaceuticals plans to collaborate with the Olivia Newton-John Cancer Research Institute in Heidelberg, Australia, on a clinical trial.
The trial is called the FET-PET in Glioblastoma (FIG) Study, and it will investigate the use of O-(2-F-18 fluoroethyl)-L-tyrosine or F-18 FET to image glioblastoma patients with PET. Telix is developing F-18 FET as a complementary agent to its TLX101 glioblastoma therapeutic candidate, it said.
The study will include up to 210 newly diagnosed adult glioblastoma patients. The research institute will lead it and has secured more than $3 million in research grant funding from the Medical Research Future Fund (MRFF), Cure Brain Cancer Foundation, and MRFF-Australian Brain Cancer Mission, according to Telix.
The company is participating in the FIG Study as both a collaborator and a funder in exchange for access to final study data to support its further development of TLX101-CDx.
